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Background: The low effectiveness of anticancer drugs remains a major unresolved obstacle to successful
chemotherapy. Recently, much evidence on the roles of miRNAs in determining drug-sensitivity/resistance has been
emerging. The relationship between miRNA-149 expression and paclitaxel chemoresistance in human ovarian
cancer cells remains largely unknown.
Methods: This study investigated the relationship between miRNA-149 expression and the sensitivity of ovarian
cancer A2780 cells to paclitaxel treatment. To achieve the down-regulation of miRNA-149 gene expression in A2780
cell line, the cells were infected with lentivirus carrying inhibitor of miRNA-149. Western blot and qRT-PCR were
used to detect relevant protein levels and the expressions of mRNAs of interest. Cell proliferation was measured by
CCK-8 assay. Flow cytometry was used to measure cell cycle and apoptosis. Transwell migration assay was used to
observe the change of migration of transfected cells.
Results: Down-regulation of miRNA-149 decreased the sensitivity of ovarian cancer A2780 cells to paclitaxel. After
paclitaxel treatment, decreased apoptosis and G2 phase ratio, increased cell migration, increased level of Bcl-2, and
decreased level of Bax were found in miRNA-149-down-regulated A2780 cells. MiRNA-149 down-regulation resulted
in increased expression of MyD88 in A2780 cells. Down-regulation of miRNA-149 in A2780 cells increased MyD88
expression and decreased their sensitivity to paclitaxel treatment.
Conclusion: Our findings suggest that miRNA-149 mediates the susceptibility of paclitaxel by regulating MyD88
expression in ovarian cancer cells.
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Ovarian cancer is a common tumor and the most lethal
malignancy of the female reproductive organs. A combin-
ation of carboplatin and paclitaxel has been widely used as
chemotherapy for ovarian cancer patients. Although the pa-
tients initially respond successfully to paclitaxel-based
chemotherapy, in most cases, they eventually become in-
sensitive to the chemotherapy [1]. Several mechanisms have
been demonstrated regarding chemoresistance to paclitaxel,
such as over-expression of the multidrug transporter P-* Correspondence: xd_kang@msn.com
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creativecommons.org/publicdomain/zero/1.0/glycoprotein [2], selective expression of beta-tubulin iso-
types [3], down-regulation of bcl-2 [4], or aberrant cell sig-
naling [5]. Nevertheless, the overall molecular mechanisms
of paclitaxel resistance have yet to be clarified.
MicroRNAs (miRNAs) are a family of short non-
coding RNAs that negatively regulate gene expression at
the post-transcriptional level. Hundreds of miRNAs have
been found in the human genome and play critical roles
in regulating cell signaling pathways such as the trans-
forming growth factor-beta, Wnt, Notch and epidermal
growth factor pathways by repressing the expression of
different mRNAs expression or through co-regulation
with transcription factors [6–9]. Consequently, dysfunc-
tion of miRNAs and their target genes can lead to a
variety of disorders. Therefore studying the role oficle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Zhan et al. Journal of Ovarian Research  (2015) 8:48 Page 2 of 10miRNAs will provide a better understanding of the mo-
lecular events involved in diverse biological processes,
and contribute to the identification of new targets in
tumor prevention and treatment.
MiRNA-149 directly targets the 3’-UTR of MyD88
mRNA and post-transcriptionally regulates MyD88 protein
expression. MiRNA-149 may be a key modulator in the
TLR/MyD88 signaling pathway in macrophages through
negative regulation of MyD88-dependent Toll-like receptor
signaling [10]. In our previous study, the expression of
MyD88 was closely associated with paclitaxel resistance in
lung cancer A549 cells [11].
The relationship between miRNA-149 expression and
paclitaxel chemoresistance in human ovarian cancer cells
remains largely unknown. In this study, we investigated
whether miRNA-149 modulates cellular sensitivity to pac-
litaxel by regulating the expression of MyD88 in ovarian
cancer A2780 cells.
Materials and methods
Cell line and maintenance
The A2780 cell line was obtained from the Institute of
Cell Biology (Shanghai, China). The cells were main-
tained in RPMI 1640 medium (Gibco-BRL, Carlsbad,
CA, USA) supplemented with 10 % fetal bovine serum
(FBS), 100 U/ml penicillin and 100 U/ml streptomycin
at 37 °C in a humidified incubator with 5 % CO2. The
cells were demonstrated to be free of mycoplasma.
Construction of miRNA-149 inhibitor and MyD88 lentiviral
vectors
MiRNA-149 inhibitor (5’-GGGAGUGAAGACACGGAG
CCAGA-3’) was inserted into the LV3-pGLV-H1-GFP/puro
lentiviral vector, and siRNA (5’-UUCUCCGAACGUGU-
CACGUdTdT-3’) was used as a negative control. MyD88
whole cDNA synthesized by GenePharma (Gene-
Pharma, Shanghai, China) was subcloned into the LV5-
pGLV-EF1a-GFP/Puro Lentiviral plasmid vector. Lentivi-
ruses expressing inhibitor against miRNA-149, MyD88,
and the controls were produced by co-transfection of
293 T cells using polybrene (GenePharma, Shanghai,
China) according to standard protocols. A2780 (5 × 104)
cells were infected with lentivirus at a MOI (multiplicity
of infection, pfu number/cell) of approximately 100 for
24 h. Cells were then transferred into complete medium.
RNA isolation and reverse transcription polymerase chain
reaction (RT-PCR)
Small RNAs were purified from differently treated
A2780 cells using an RNA purification kit (TIANGEN
Biotech, Beijing, China). Total RNA was extracted with
Trizol reagent according to the protocol described by
the supplier (TakaRa, Dalian, China). First-strand cDNA
was synthesized from 1 μg of total RNA in a 20-μl reactionmixture using the PrimeScript RT reagent kit (TakaRa,
Dalian, China). Quantitative real-time PCR-based gene ex-
pression analysis was performed on a real-time PCR instru-
ment (7300, Step One Plus, Applied Biosystems, USA)
using a standard SYBR-Green PCR kit. The parameters
used for all PCR reactions were as follows: One cycle of
95 °C for 2 min, followed by 40 cycles of 95 °C for 15 s, and
60 °C for 30 s. Specific primer sets were used for RT-PCR
of the U6 control, miR-149, β-actin control, and MyD88.
The relative expression of each target gene was calculated
using the 2-ΔΔct method.
Analysis of apoptosis
The percentage of apoptotic cells was quantitated using
the Annexin V-PE Kit (Becton-Dickinson) according
to the manufacturer's instructions. Stained cells were
analyzed by flow cytometry during the first 30 min of
staining. ≥10,000 cells were measured using a FACScan
instrument (Becton-Dickinson) and the data were ana-
lyzed using FlowJo software (Tree Star Inc.).
Cytotoxicity assay
Cell viability was assessed using the Cell Counting Kit 8
(CCK-8) (Dojindo Laboratories, Kumamoto, Japan) assay.
6 × 104 A2780 cells (100 μl) were seeded into 96-well
plates. After 24 h of incubation, paclitaxel (Sigma) was
added at concentrations of 0 μM, 0.1 μM, 0.2 μM, 0.3 μM,
0.4 μM and 0.5 μM (each concertration were done repeat
five experiments); the cells were then incubated for 48 h.
After 48 h, 10 μl of CCK-8 solution was added to each
well, followed by 4 h of incubation at 37 °C. The OD
values were read at dual wave lengths of 450 nm and
630 nm to determine cell viability using a microplate
reader (Thermo Fisher Labsystems).
Analysis of cell cycle
Cells (2 × 106) were pelleted by spinning for 5 min at
1000 rpm and 4 °C and resuspended in 1 ml of cold PBS.
After fixation by adding 4 ml of absolute ethanol, the cells
were centrifuged and resuspended in 1 ml of PBS. Then,
100 μl of 200 μg/ml DNase-free RNaseA was added to the
cell suspension and incubated for 30 min at 37 °C. The
cells were stained with 100 μl of 1 mg/ml propidium
iodide (light sensitive) and incubated for 5–10 min at
room temperature before analysis.
Western blot
The protein concentration of each sample was determined
by BCA Protein Assay Kit (Beyotime, Jiangsu, China). Equal
amounts of protein were loaded and separated discontinu-
ously on 12 % sodium dodecyl sulfate-polyacrylamide gels
(SDS-PAGE), and subsequently transferred onto a PVDF
membrane (Amersham Pharmacia, UK). The mem-
brane was then incubated in TBST blocking solution
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taining 5 % skim milk for 2 h at room temperature,
followed by separate incubation with primary antibodies
against Bax, MyD88, Bcl-2 (Cell Signaling, USA) and β-
actin (Beyotime, Jiangsu, China) overnight at 4 °C. After
washing, the membrane was incubated with HRP-
conjugated anti-mouse, anti-rabbit, or anti-goat secondary
antibodies for 2 h. After several washes, the immunoblot
was detected with enhanced chemi-luminescence re-
agent (Pierce Biotechnology, USA) according to the
manufacturer's instructions.Immunocytochemistry
Expression of MyD88 protein was determined using im-
munocytochemistry. In total, 1 × 105 cells were seeded
into a Millicell EZ Slide (Millipore, Shanghai, China).
After 24 h of incubation, cells were fixed on slides using
4 % paraformaldehyde. The cells were permeabilized for
10 min with 0.1 % Triton X-100 in PBS and blocked with
blocking buffer (2 % BSA, 0.1 % Triton X-100) for 30 min
at room temperature. After blocking, the cells were
washed with PBS and incubated overnight with rabbit
anti-human MyD88 antibodies (Sigma, Shanghai, China)
at 4 °C. On the following day, the cells were washed three
times with PBS, and then incubated with Cy3-labeled goat
anti-rabbit IgG (H + L) (Beyotime, China) for 1 h followed
by washing with PBS three times.Cell migration assay
Cell migration were evaluated using the Transwell
Permeable Support (Corning) according to the manu-
facturer’s instructions. Five 200-multiple microscopicFig. 1 Inhibition of cell growth by paclitaxel was determined in A2780 cell
48 h with the indicated concentrations. a The expression level of miRNA-14
Asterisk refers to p < 0.01. b The inhibition of cell growth by paclitaxel was
treatment was performed for 48 h with the indicated concentrationsfields were randomly selected to calculate the total
count of the invaded or migrated cells. All assays were
conducted three times.
Statistical analysis
For all analyses, the measurements obtained from the
groups were expressed as the means ± SD for all data
determined. Statistical analysis was performed using
an unpaired Student's t-test followed by Tukey's test.
P < 0.05 was considered statistically significant.
Results
Decreased sensitivity of A2780 cells to paclitaxel
treatment after down-regulation of miRNA-149
We used a lentiviral vector expressing inhibitor against
miRNA-149 to achieve down-regulation of miRNA-149
in ovarian cancer A2780 cells. Real-time PCR analysis
showed that the expression of miRNA-149 in cells
transduced with inhibitor to miRNA-149 was markedly
lower than that of control A2780 cells (Fig. 1a). In the
presence of paclitaxel, the proliferation of A2780 cells
was significantly inhibited in the control (Fig. 1b), sug-
gesting that down-regulation of miRNA-149 decreased
the sensitivity of A2780 cells to paclitaxel treatment.
Down-regulation of miRNA-149 increases the expression
of MyD88 in A2780 cells
Using miRanda (http://www.microrna.org/) and TargetScan
(http://www.targetscan.org/) to analysis the miRNA-149
target sites of MyD88 (Fig. 2a). To assess whether
miRNA-149 is involved in the regulation of MyD88
expression in A2780 cells, the expression of MyD88s after miRNA-149 knockdown. Paclitaxel treatment was conducted for
9 was measured using quantitative real-time PCR in different groups.
determined in A2780 cells after miRNA-149 down-regulation. Paclitaxel
Fig. 2 Down-regulation of miRNA-149 increased MyD88 expression in A2780 cells. a Seguence of potential binding site of miRNA-149 in the
3’-UTR of MyD88 mRNA. b The mRNA level of MyD88 was measured using quantitative real-time PCR in different groups as indicated. Asterisk refers to
p < 0.01. c MyD88 protein expression was determined by western blot. d MyD88 protein expression was determined by immunocytochemistry. Red
indicates staining of MyD88
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and immunocytochemistry. MiRNA-149 was capable of al-
tering MyD88 expression at the mRNA level in these cells
and consequently was able to up-regulate MyD88 mRNA
expression by 1.67 fold as compared to the negtive
control (Fig. 2b). Furthermore, the overexpression of
MyD88 was verified by western blot and immunohis-
tochemistry (Fig. 2c and d). Collectively, the data indicatethat miRNA-149 has the potential to regulate MyD88 ex-
pression in ovarian cancer cells.
Decreased sensitivity of A2780 cells to paclitaxel
treatment after over-expression of MyD88
To determine the effects of elevated MyD88 expression in
ovarian cancer, MyD88 was over-expressed in ovarian can-
cer A2780 cells using a lentiviral vector. Over-expression
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overexpressing cells were refractory to growth inhibition by
paclitaxel when compared to the control (Fig. 3b).
Effects of miRNA-149 down-regulation on the cell cycle of
A2780 cells
It is well known that paclitaxel arrests the cell cycle at
the G2 phase. To analyze the impact of miRNA-149
expression on paclitaxel’s interference with the cell
cycle in A2780 cells, DNA flow cytometric analysis
was performed to determine the effect of paclitaxel on
the cell cycle of A2780 cells with different expression
levels of miRNA-149. A G2 phase increase was found
in A2780 cells with miRNA-149 down-regulation and
NC cells after treatment with paclitaxel (Fig. 4a and b).
The G2 phase fold change was significantly decreased in
cells with miRNA-149 down-regulation (Fig. 4c).
Regulation of apoptosis by miRNA-149 down-regulation
in A2780 cells
Cells were treated with paclitaxel for 48 h prior to the
measurement of apoptotic cells with Annexin V. As
shown in Fig. 5a and b, a significant decrease in the
percentage of apoptotic cells was observed in A2780
cells with miRNA-149 down-regulation (P < 0.01).
Down-regulation of miRNA-149 decreased the expres-
sion of Bax in A2780 cells and increased the expres-
sion of Bcl-2 (Fig. 5c and d). These results suggest
that miRNA-149 may be associated with the cell apop-
tosis induced by paclitaxel in A2780 cells.
Down-regulation of miRNA-149 promotes the migration
of A2780 cells
As shown in Fig. 6a, A2780 cells migrated faster when
miRNA-149 was down-regulated, as indicated by theFig. 3 Inhibition of cell growth by paclitaxel was determined in A2780 cell
conducted for 48 h with the indicated concentrations. a The mRNA level o
groups (experimental vs. NC control). b The inhibition of cell growth by pa
Asterisk refers to p < 0.01number of migrated cells within a fixed time (Fig. 6b).
These data suggest that down-regulation of miRNA-149
may promote the migration of A2780 cells.
Discussion
An increasing number of studies suggests that miRNAs
play important roles in diverse biological processes, such
as development, cell proliferation, apoptosis, fat metab-
olism, and oncogenesis [12]. Over the years, attention
has focused on the role of miRNAs in reversing drug re-
sistance and regulating the sensitivity of cancer cells to
chemotherapeutants [13, 14]. Dysregulated expression of
various miRNAs has been found in ovarian carcinoma.
Dysregulation of the microRNA let-7e and down-
regulation of miR-30c, miR-130a, and miR-335 indicate
direct involvement of some miRNAs in the development
of chemoresistance [15]. Down-regulation of miR-21 pro-
motes apoptosis and chemosensitivity in ovarian cancer
[16]. MiRNA-370 [17], miRNA-93 [18], and miRNA-100
[19] are related to the chemosensitivity of ovarian cancer.
Aberrant expression of miR-149 has been reported
in many cancers including colorectal cancer [20],
nasopharyngeal carcinoma [21], clear-cell renal cell
carcinoma [22], prostate cancer [23], and gastric can-
cer [24]. Li et al. [25] found that over-expression of
miR-149 inhibited glioblastoma cell proliferation and
migration. As a methylation-sensitive miRNA, miR-149
plays an important role as a tumor suppressor in colorec-
tal cancer with prognostic and therapeutic implications
[26]. However, the relationship between miRNA-149
expression and the sensitivity to paclitaxel in ovarian
cancer remains unknown. Our results show that
down-regulation of miRNA-149 decreases the sensitiv-
ity of A2780 cells to paclitaxel treatment.
MyD88 is a key molecular cohesion molecule in the
Toll-like receptor (TLR) signaling pathway. Elevateds after over-expression of the MyD88 gene. Paclitaxel treatment was
f MyD88 was measured using quantitative real-time PCR in different
clitaxel was determined in A2780 cells after MyD88 overexpression.
Fig. 4 Cell cycle analysis of A2780 cells treated with paclitaxel in relation to miRNA-149 down-regulation. a Flow cytometric analysis of the cell
cycle with miRNA-149-down-regulated and control cells. b G2 phase analysisof the cell cycle with miRNA-149-down-regulated and control cells.
c Quantitative analysis of the fold change of the G2 phase ratio after paclitaxel treatment in A2780 cells with down-regulation of miRNA-149. Fold
change of G2 phase was calculated as: Fold change of G2 phase = G2 phase with paclitaxel treatment/G2 phase without paclitaxel treatment
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cells in various types of cancer [27–29]. Expression of
MyD88 was elevated in more than 70 % of patients
with EOC and has been considered as an indicator of
tumor metastasis and paclitaxel chemoresistance, in
addition to a factor for significantly poor prognosis
[30, 31]. Overexpression of MyD88 decreases thesensitivity to paclitaxel in ovarian cancer and hepato-
cellular carcinoma cells [32, 33].
In the present study, expression of miRNA-149 in
A2780 cells was decreased by specific inhibitor using
lentiviral vectors. miRNA-149 down-regulation resulted
in increased expression of MyD88 in A2780 cells. The
results are consistent with previous results that over-
Fig. 5 Analysis of apoptosis in A2780 cells with miRNA-149 down-regulation. a Apoptosis in miRNA-149-down-regulated A2780 cells was analyzed
by Annexin V-PE staining after treatment with paclitaxel. Data are presented as the mean ± SD of three independent experiments. b Apoptosis
rates of miRNA-149-down-regulated and control cells. Asterisk refers to p < 0.01. c Real-time PCR analysis of Bax and Bcl-2 mRNA expression. The
results were normalized to the amount of β-actin. Each value represents the average of 3 independent experiments. Asterisk refers to p < 0.01.
d Western blot analysis of Bcl-2, Bax and MyD88 proteins expression in each group. β-actin expression served as the loading control
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with decreased MyD88 at the protein level [10]. In the
presence of paclitaxel, the proliferation of A2780 cells
was significantly inhibited in the control group, suggesting
that miRNA-149 down-regulation may decrease the
sensitivity of A2780 ovarian cancer cells to paclitaxel
treatment. Furthermore, the sensitivity to paclitaxel
was decreased in MyD88 over-expressing A2780 cells.Paclitaxel is an effective anti-cancer drug against a
variety of cancers. Paclitaxel reduces the dynamicity of
the mitotic spindle, causing G2/M cell cycle arrest [34].
In our study, we analyzed the cell cycle of A2780 cells
with miRNA-149 down-regulation after treatment with
paclitaxel for 48 h. The G2/M phase transition was
decreased significantly in A2780 cells in the transduced
group compared to the control group. The reduction in
Fig. 6 Down-regulation of miRNA-149 promotes A2780 ovarian cancer cell migration in vitro. a Cell migration assays were performed on A2780
cells with down-regulation of miRNA-149 and control cells. b Migrated cells were visualized by staining with crystal violet and quantitated using a
cell counter. Asterisk refers to p < 0.01
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of cells at the G0/G1 phase suggest that miRNA-149 is
associated with paclitaxel chemosensitivity.
Depending on the cell type and drug, cells undergo
apoptosis during mitotic arrest or abnormal mitosis [35].
Paclitaxel directly induces apoptosis of several types oftumor cells through a variety of mechanisms, such as
phosphorylation of Bcl-2, activation of caspase-3 and
caspase-9, and the mitogen-activated protein kinase sig-
nal transduction pathway [36–38]. In the present study,
flow cytometric assays were used to detect the apoptosis of
A2780 cells after down-regulation of miRNA-149. We
Zhan et al. Journal of Ovarian Research  (2015) 8:48 Page 9 of 10found that down-regulation of miRNA-149 decreased the
apoptosis induced by paclitaxel when compared to the
control group. Furthermore, we showed that down-
regulation of miRNA-149 in A2780 cells enhanced the
expression of the anti-apoptotic protein Bcl-2 and
inhibited the expression of the pro-apoptotic protein
bax, which may have led to paclitaxel resistance. Our
previous study demonstrated that [11] MyD88 was
involved in anti-apoptosis and drug resistance through
the alteration of bax and bcl-2 levels.
In this study, we have shown that reduced expression of
miRNA-149 enhanced the migration of A2780 cells. Chan
et al. showed that down-regulation of microRNA-149
suppressed cell migration/invasion and metastasis in
breast cancer by targeting migration and invasion-related
genes [39]. Taken together, our findings suggest that
miR-149 facilitates the migration of ovarian cancer
cells through regulation of MyD88.
Conclusions
Our data demonstrate that miRNA-149 is associated with
the cellular response to paclitaxel through regulation of
MyD88 in ovarian cancer cells. These findings provide
novel insights into the role of miR-149 in the chemosensi-
tivity of human ovarian cancer and indicate that miR-149
could be a putative drug target for therapeutic intervention.
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